# UFPT earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/UFPT) · [Earnings tab](https://www.lopjlb.com/stock/UFPT?tab=earnings)

Updated: 2026-08-03T04:37:52

Quarters analyzed: 5

## Cross-quarter narrative

Across the five UFPT CallCards the company moved from a breakout first quarter in 2025, with revenue up 41% and medical sales soaring 50%, to a more measured 19.5% full‑year growth and a modest 4.1% Q1‑2026 increase. Early calls highlighted rapid AJR safe‑patient‑handling growth but also flagged labor turnover that eroded margins. By Q4‑2025 the firm reported a compressed gross margin (28.2%) driven by $6.3 M AJR labor costs, yet operating margin stayed within its 17‑20% target as remediation began. The Dominican Republic (DR) expansion stayed on track, though program‑ramp‑up delays and a February ransomware incident introduced execution risk. Customer‑concentration concerns persisted because the largest client’s volume details remain confidential despite a contract extension. M&A activity remained active but disciplined, and tariff exposure stayed minimal. By Q1‑2026 labor inefficiencies were improving, wound‑care inventory drag lingered, and the CEO transition proceeded as planned. Overall the narrative shifts from high‑growth momentum and emerging labor challenges to a phase of operational stabilization, margin recovery, and heightened focus on execution risk and cybersecurity.

## Latest CallCard · Q1

UFPT Q1 revenue +4.1% driven by medical +5.9%; four program launches ramping, capacity expanding in DR; AJR labor inefficiencies improving; wound care inventory drag ~3 quarters; M&A disciplined; CEO transition to Mitch Rock in June.','tone':{'mgmt':0.7,'mgmt_rationale':'Management highlighted stron

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q1:** UFPT Q1 revenue +4.1% driven by medical +5.9%; four program launches ramping, capacity expanding in DR; AJR labor inefficiencies improving; wound care inventory drag ~3 quarters; M&A disciplined; CEO transition to Mitch Rock in June.','tone':{'mgmt':0.7,'mgmt_rationale':'Management highlighted stron
- **2025 Q4:** UFPT reports 19.5% revenue growth to $602.8M in 2025, extends largest customer contract, progresses DR expansion, resolves AJR labor issues, and manages cyberattack with minimal impact. EPS up 15.4% despite $6.3M labor inefficiencies; leverage reduced to 1.1x. CEO transition on track for June.
- **2025 Q3:** —
- **2025 Q2:** UFPT Q2: 37% revenue growth (5% organic), medical +46%, RAS +7%; AJR labor turnover hurts margins ($1.2M Q2, $2.5M Q3), two acquisitions closed, RAS pipeline expanding, DR expansion on track. Q3 revenue impact $7M, op income impact $2.5M; Q4 margin rebound expected. Tariff inflation ~$9M annually, p
- **2025 Q1:** UFPT Q1: revenue +41%, medical +50% driven by AJR safe patient handling; robotic surgery modest 2025 growth; DR expansion on track; tariffs minimal direct impact; active M&A pipeline.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management described a "strong first quarter" and said "We continue to be 

## Theme arcs

- **Revenue growth** (improving): From 41% Q1‑2025 surge to 19.5% annual growth and continued 4.1% Q1‑2026 rise
- **Medical segment expansion** (improving): Consistently strong double‑digit growth across all quarters
- **Robotic assisted surgery (RAS) pipeline** (stable): Modest growth reported, pipeline expanding without major acceleration
- **AJR labor issues** (resolved): Initial turnover hurt margins; remediation on track and inefficiencies declining
- **DR expansion execution** (deteriorating): On‑track expansions faced program‑ramp delays and transfer timing risks
- **Cybersecurity risk** (new): Ransomware attack in Feb‑2025 introduced new exposure
- **Customer concentration visibility** (stable): Largest customer volumes undisclosed; contract extension adds volume but limits insight
- **Margin pressure** (improving): Gross margin compressed by labor costs, but operating margin stayed within target as labor improves
- **M&A activity** (stable): Active pipeline and disciplined execution across calls
- **Backlog level** (stable): Safe‑patient‑handling backlog higher than disclosed, work‑down expected through 2026

## Fear persistence

- **Cybersecurity** [new]: Ransomware attack detected Feb 14 2025, investigation ongoing
- **Labor** [recurring]: AJR attrition caused $6.3 M inefficiency in 2025, remediation underway
- **Customer concentration** [recurring]: Largest customer volumes undisclosed, limiting visibility
- **Execution (DR expansion)** [recurring]: Program‑ramp and transfer timing risks affecting DR rollout
- **Backlog** [recurring]: Safe‑patient‑handling backlog higher than disclosed, gradual work‑down planned

## Guidance path

2025 Q1:vague → 2025 Q2:vague → 2025 Q3:vague → 2025 Q4:vague → 2026 Q1:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/UFPT`